Novartis : T3 2024 au-dessus des attentes. Guidance FY relevée
>Excellente performance des produits phares - Le T3 ressort au-dessus des attentes au niveau des ventes (+2% vs Css) et du core BPA (+6% vs Css). Les ventes progressent de 10% tcc (9% en publié) tirées par tous les produits phares : Entresto (26%cc, -1% vs Cs), Cosentyx (28%cc, +8% vs Cs), Kisqali (43%cc, +1% vs Cs) et Kesimpta (28%cc, +1% vs Cs) et Pluvicto (50%cc, +2% vs Cs). Soulignons que c. 60% du beat provient de l’excellente performance de Cosentyx tiré par les...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.